T Sakai received honoraria from Astra Zeneca, Chugai, Kyowa-Kirin, Pfizer, Daiichi-Sankyo, Exact Science, Canon, and Ethicon. GK received honoraria from Lilly, Kyowa Kirin, Daiichi Sankyo, AstraZeneca Pfizer, and Chugai. T Shien received honoraria from Daiichi-Sankyo, Pfizer, Chugai, and Lilly. SA received honoraria from Astra Zeneca, Chugai, Daiichi Sankyo, Eli Lilly, and Pfizer. TA received honoraria from Pfizer, Chugai, Eli Lilly, Astra Zeneca and Kyowa Kirin. MI received honoraria from Astra Zeneca, Chugai, Pfizer, Taiho, Novartis and Nihon Kayaku. SK received honoraria from Pfizer, Daiichi-Sankyo, Chugai, Astra Zeneca and Kyowa Kirin. MS received honoraria from Chugai, Kyowa Kirin, Pfizer, Astra Zeneca and Eli Lilly. Kaori Terata received honoraria and payment for expert testimony from Astra Zeneka, Daiichi-Sankyo, Chugai, Pfizer, Eli Lilly and Taiho. Koichi Tomita received honoraria from Ethicon. CY does not have any Disclosure. YY received research funding and honoraria from Chugai, Kyowa-Kirin, Eisai, Daiichi-Sankyo, Nippon-Kayaku, Taiho, Takeda, Lilly, Pfizer, Novartis and Takeda, MSD, Sysmex and Exact Science. YU, and he also a member of the Board of Directors in Japanese Breast Cancer Society and Japan Breast Cancer Research Group. HI received Grants and consultant fees from Chugai, Daiichi Sankyo, Astra Zeneca, Lilly, MSD, Pfizer and Gilead and honoraria from Daiichi-Sankyo, Chugai, Astra, Lilly, MSD, Pfizer, Taiho, and Kyowa Kirin. SS received Grants and honoraria from Taiho, Eisai, Chugai, Takeda, MSD, AstraZeneca, Daiichi-Sankyo, Novartis, Takeda, Daiichi Sankyo Eli Lilly, Pfizer, Taiho, Ono and Nippon Kayaku. He is also an advisory Board of Chugai, Astra Zeneca, Eli Lilly, Pfizer, Kyowa Kirin Daiichi Sankyo and MSD and the executive board member of JBCRG, JBCS JSMO, and BIG. The other authors declare no relevant conflicts of interest.